Volume 9 Supplement 1

Proceedings of the 2009 Drug Discovery for Neurodegeneration Conference

Proceedings

Edited by Diana W Shineman and Howard M Fillit

The conference and the publication of these proceedings were supported by conference grant U13-AG031125 from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke and the National Institutes of Health's Office of Rare Diseases. Other sponsors: CoMentis, Eli Lilly and Company, sanofi-aventis, Biogen Idec and The Michael J. Fox Foundation for Parkinson's Research

Drug Discovery for Neurodegeneration Conference. Go to conference site.

Washington, DC, USA2-3 February 2009

Meeting the unique challenges of drug discovery for neurodegenerative diseases

Authors: Diana W Shineman and Howard M Fillit

Citation: BMC Neurology 2009 9(Suppl 1):I1

Content type: Introduction Published on: 12 June 2009
- View Full Text
- View PDF
ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective

The advent of early absorption, distribution, metabolism, excretion, and toxicity (ADMET) screening has increased the attrition rate of weak drug candidates early in the drug-discovery process, and decreased t...

Authors: Katya Tsaioun, Michel Bottlaender and Aloise Mabondzo

Citation: BMC Neurology 2009 9(Suppl 1):S1

Content type: Proceedings Published on: 12 June 2009
- View Full Text
- View PDF
The basics of preclinical drug development for neurodegenerative disease indications

Preclinical development encompasses the activities that link drug discovery in the laboratory to initiation of human clinical trials. Preclinical studies can be designed to identify a lead candidate from sever...

Authors: Karen L Steinmetz and Edward G Spack

Citation: BMC Neurology 2009 9(Suppl 1):S2

Content type: Proceedings Published on: 12 June 2009
- View Full Text
- View PDF
Characteristics of compounds that cross the blood-brain barrier

Substances cross the blood-brain barrier (BBB) by a variety of mechanisms. These include transmembrane diffusion, saturable transporters, adsorptive endocytosis, and the extracellular pathways. Here, we focus ...

Authors: William A Banks

Citation: BMC Neurology 2009 9(Suppl 1):S3

Content type: Proceedings Published on: 12 June 2009
- View Full Text
- View PDF

Proceedings of the 2009 Drug Discovery for Neurodegeneration Conference

Proceedings

Meeting the unique challenges of drug discovery for neurodegenerative diseases

ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective

The basics of preclinical drug development for neurodegenerative disease indications

Characteristics of compounds that cross the blood-brain barrier

Important information

Annual Journal Metrics

Follow

BMC Neurology

Contact us